Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2220

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2220
---
 biotechnology and biopharmaceutical industries, we collaborate with and/or employ and intend to collaborate with and/or
employ individuals who were previously affiliated with universities or other biotechnology or biopharmaceutical companies, including
those that operate in the same indications we do. Although no claims against us are currently pending, and although we try to ensure
that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual
property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary
to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings
relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management
personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have
a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our
operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources
to adequately conduct such litigation or proceedings. We may be unable to sustain the costs of such litigation or proceedings as a result
of our currently limited financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
intellectual property related proceedings could adversely affect our ability to compete in the marketplace.

We
may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.

Because
our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth
of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.

100

Our
product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others.
We may develop products containing our drug substance and pre-existing biopharmaceutical compounds. We may be unable to acquire or in-license
any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we